Incidence and Predictors of Relapse After Weaning Immune Suppressive Therapy in Cardiac Sarcoidosis.

[1]  M. Rosenbach,et al.  Stable Extent of Recurrently Active Cardiac and Cutaneous Sarcoidosis , 2021, Frontiers in Medicine.

[2]  Hiroshi Ito,et al.  Clinical outcomes of patients with isolated cardiac sarcoidosis confirmed by clinical diagnostic criteria. , 2021, International journal of cardiology.

[3]  M. Ruivard,et al.  Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies , 2021, European Respiratory Journal.

[4]  N. Hagiwara,et al.  Prognosis and recurrence in cardiac sarcoidosis: Serial assessment of BMIPP SPECT and FDG-PET , 2021, Journal of Nuclear Cardiology.

[5]  L. Biard,et al.  Cardiac sarcoidosis: A long term follow up study , 2020, PloS one.

[6]  Y. Kihara,et al.  JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis　- Digest Version. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[7]  V. Vedantham,et al.  Long‐Term Corticosteroid‐Sparing Immunosuppression for Cardiac Sarcoidosis , 2019, Journal of the American Heart Association.

[8]  M. Akçakaya,et al.  Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis. , 2019, Circulation. Arrhythmia and electrophysiology.

[9]  P. Dieudé,et al.  Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs. , 2019, International journal of cardiology.

[10]  D. Okada,et al.  Isolated cardiac sarcoidosis: A focused review of an under-recognized entity , 2018, Journal of Nuclear Cardiology.

[11]  C. Donatelli,et al.  Toxicity risk from glucocorticoids in sarcoidosis patients. , 2017, Respiratory medicine.

[12]  P. Cluzel,et al.  Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. , 2017, Archives of cardiovascular diseases.

[13]  Amit R. Patel,et al.  Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac Sarcoidosis. , 2017, JACC. Cardiovascular imaging.

[14]  A. Leenhardt,et al.  High mass (>18g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. , 2016, International journal of cardiology.

[15]  T. Aiba,et al.  Effect of Discontinuation of Prednisolone Therapy on Risk of Cardiac Mortality Associated With Worsening Left Ventricular Dysfunction in Cardiac Sarcoidosis. , 2016, The American journal of cardiology.

[16]  Amit R. Patel,et al.  Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction , 2016, Circulation. Cardiovascular imaging.

[17]  Hiroshi Ito,et al.  Comparison of outcomes in patients with probable versus definite cardiac sarcoidosis. , 2015, The American journal of cardiology.

[18]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[19]  Shawn D. Feinstein,et al.  Magnetic Resonance Imaging for Identifying Patients With Cardiac Sarcoidosis and Preserved or Mildly Reduced Left Ventricular Function at Risk of Ventricular Arrhythmias , 2014, Circulation. Arrhythmia and electrophysiology.

[20]  Amit R. Patel,et al.  HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. , 2014, Heart rhythm.

[21]  W. Shimizu,et al.  Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis , 2014, Heart.

[22]  A. Bast,et al.  Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide , 2013, Current opinion in pulmonary medicine.

[23]  H. Shimokawa,et al.  Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. , 2012, Journal of cardiology.

[24]  J. Piette,et al.  Cardiac Sarcoidosis: A Retrospective Study of 41 Cases , 2004, Medicine.

[25]  M. Isobe,et al.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. , 2001, The American journal of cardiology.

[26]  M. Judson,et al.  An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. , 1999, Chest.

[27]  A. Ha,et al.  Cardiac Sarcoidosis. , 2016, Journal of the American College of Cardiology.

[28]  F. Wamboldt,et al.  Management of cardiac sarcoidosis in the United States: a Delphi study. , 2012, Chest.